These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31885051)

  • 1. The Practice of Pharmaceutics and the Obligation to Expand Access to Investigational Drugs.
    Buckley M; O'neil C
    J Med Philos; 2020 Mar; 45(2):193-211. PubMed ID: 31885051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free to Choose: A Moral Defense of the Right-to-Try Movement.
    Brodrick M
    J Med Philos; 2020 Jan; 45(1):61-85. PubMed ID: 31922578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do Physicians Have a Duty to Discuss Expanded Access to Investigational Drugs with their Patients? A Normative Analysis.
    Vermeulen SF; Hordijk M; Visser RJ; Bunnik EM
    J Law Med Ethics; 2023; 51(1):172-180. PubMed ID: 37226748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should Social Value Obligations be Local or Global?
    Nayak R; Shah SK
    Bioethics; 2017 Feb; 31(2):116-127. PubMed ID: 28060432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
    Bunnik EM; Aarts N; van de Vathorst S
    Health Policy; 2018 Sep; 122(9):977-983. PubMed ID: 29935731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of common ethical justifications for compassionate use programs for experimental drugs.
    Raus K
    BMC Med Ethics; 2016 Oct; 17(1):60. PubMed ID: 27756370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
    Caplan AL; Teagarden JR; Kearns L; Bateman-House AS; Mitchell E; Arawi T; Upshur R; Singh I; Rozynska J; Cwik V; Gardner SL
    J Med Ethics; 2018 Nov; 44(11):761-767. PubMed ID: 29982174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge of assuring continued post-trial access to beneficial treatment.
    Grady C
    Yale J Health Policy Law Ethics; 2005; 5(1):425-35. PubMed ID: 15742586
    [No Abstract]   [Full Text] [Related]  

  • 9. Is procreative beneficence obligatory?
    Saunders B
    J Med Ethics; 2015 Feb; 41(2):175-8. PubMed ID: 24523029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. For-profit clinical trials in developing countries--those troublesome patient benefits.
    Schuklenk U
    Am J Bioeth; 2010 Jun; 10(6):52-4. PubMed ID: 20526975
    [No Abstract]   [Full Text] [Related]  

  • 11. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.
    Fountzilas E; Said R; Tsimberidou AM
    Expert Opin Investig Drugs; 2018 Feb; 27(2):155-162. PubMed ID: 29353505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study.
    Sofaer N; Thiessen C; Goold SD; Ballou J; Getz KA; Koski G; Krueger RA; Weissman JS
    J Med Ethics; 2009 Mar; 35(3):183-8. PubMed ID: 19251971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Just health care (I): Is beneficence enough?
    Fleck LM
    Theor Med; 1989 Jun; 10(2):167-82. PubMed ID: 2675374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reciprocity-based reasons for benefiting research participants: most fail, the most plausible is problematic.
    Sofaer N
    Bioethics; 2014 Nov; 28(9):456-71. PubMed ID: 24602060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provision of HIV treatment in HIV preventive vaccine trials: a developing country perspective.
    Slack C; Stobie M; Milford C; Lindegger G; Wassenaar D; Strode A; Ijsselmuiden C
    Soc Sci Med; 2005 Mar; 60(6):1197-208. PubMed ID: 15626517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical, legal, and ethical issues in expanded access to investigational drugs.
    Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952
    [No Abstract]   [Full Text] [Related]  

  • 20. Participation in biomedical research is an imperfect moral duty: a response to John Harris.
    Shapshay S; Pimple KD
    J Med Ethics; 2007 Jul; 33(7):414-7. PubMed ID: 17601870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.